Tirzepatid

Tirzepatide is a dual GLP-1/GIP receptor agonist ("twincretin") and the successor to semaglutide. In trials, average weight loss exceeded 20 % - often with good tolerability. Evidence level 4.

How does tirzepatide work?

Unlike semaglutide (GLP-1 only), tirzepatide targets two gut hormones: GLP-1 and GIP. The synergy suppresses appetite more strongly and improves insulin sensitivity more efficiently. GIP also appears to counteract some of the nausea typical of GLP-1 agonists. Because it engages two complementary pathways, tirzepatide tends to deliver deeper metabolic effects than single-hormone drugs.

What is tirzepatide used for?

For users, the dual approach usually means deeper, faster weight loss and a particularly good reduction of visceral (organ) fat. Eli Lilly markets it as Mounjaro (type 2 diabetes) and Zepbound (weight reduction). It is one of the most effective broadly available metabolic medicines, which is why interest in it has grown sharply since 2023. To compare it with related options, see semaglutide and retatrutide.

What does the evidence say?

The global SURMOUNT trials (Phase 3) were outstanding; tirzepatide is approved in the USA and Europe. It is currently regarded as the most potent broadly available drug of its class. The next generation is retatrutide. To work out injection volumes, use the dosage calculator. Want to keep your protocols in one place? Create a free account.

Note: Educational information, not medical advice. Many of these substances are experimental and not approved for human use.